AIM: Prostaglandin G/H synthase 2 (PTGS2 or COX2) is one of the key factors in the cellular response to inflammation. PTGS2 is expressed in the affected intestinal segments of patients with inflammatory bowel diseases (IBD). In IBD patients, non-steroidal anti-inflammatory drugs, which have been shown to reduce both the production and activity of PTGS2, may activate IBD and aggravate the symptoms. We aimed at examining genetic variants of PTGS2 that may be risk factors for IBD. METHODS: We have genotyped 291 individuals diagnosed with IBD and 367 controls from the Dutch population for the five most frequent polymorphisms of the PTGS2 gene. Clinical data were collected on all patients. DNA was extracted via normal laboratory methods. Genotyping was carried out using multiplex PCR followed by the Invader Assay and the 5' exonuclease assay (TaqMan). New polymorphism screening was performed by pre-screening with denaturing high-performance liquid chromatography, followed by fluorescent sequencing. RESULTS: Allele 5209G was weakly associated with Crohn's disease (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.03-2.57), and allele 8473T with ulcerative colitis (OR 1.50, 95%CI 1.00-2.27). The haplotype including both alleles showed a strong association with IBD (OR 13.15, 95%CI 3.17-116.15). This haplotype, while rare (-0.3%) in the general population, is found more frequently in the patients (3.5%). CONCLUSION: Our data suggest that this haplotype of PTGS2 contributes to the susceptibility of IBD.
AIM: Prostaglandin G/H synthase 2 (PTGS2 or COX2) is one of the key factors in the cellular response to inflammation. PTGS2 is expressed in the affected intestinal segments of patients with inflammatory bowel diseases (IBD). In IBD patients, non-steroidal anti-inflammatory drugs, which have been shown to reduce both the production and activity of PTGS2, may activate IBD and aggravate the symptoms. We aimed at examining genetic variants of PTGS2 that may be risk factors for IBD. METHODS: We have genotyped 291 individuals diagnosed with IBD and 367 controls from the Dutch population for the five most frequent polymorphisms of the PTGS2 gene. Clinical data were collected on all patients. DNA was extracted via normal laboratory methods. Genotyping was carried out using multiplex PCR followed by the Invader Assay and the 5' exonuclease assay (TaqMan). New polymorphism screening was performed by pre-screening with denaturing high-performance liquid chromatography, followed by fluorescent sequencing. RESULTS: Allele 5209G was weakly associated with Crohn's disease (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.03-2.57), and allele 8473T with ulcerative colitis (OR 1.50, 95%CI 1.00-2.27). The haplotype including both alleles showed a strong association with IBD (OR 13.15, 95%CI 3.17-116.15). This haplotype, while rare (-0.3%) in the general population, is found more frequently in the patients (3.5%). CONCLUSION: Our data suggest that this haplotype of PTGS2 contributes to the susceptibility of IBD.
Authors: Richard M Single; Diogo Meyer; Jill A Hollenbach; Mark P Nelson; Janelle A Noble; Henry A Erlich; Glenys Thomson Journal: Genet Epidemiol Date: 2002-02 Impact factor: 2.135
Authors: George P Christophi; Rong Rong; Philip G Holtzapple; Paul T Massa; Steve K Landas Journal: Inflamm Bowel Dis Date: 2012-03-29 Impact factor: 5.325
Authors: Hilbert S de Vries; Rene H M te Morsche; Martijn G H van Oijen; Iris D Nagtegaal; Wilbert H M Peters; Dirk J de Jong Journal: PLoS One Date: 2010-11-24 Impact factor: 3.240
Authors: David Meriwether; Dawoud Sulaiman; Carmen Volpe; Anna Dorfman; Victor Grijalva; Nasrin Dorreh; R Sergio Solorzano-Vargas; Jifang Wang; Ellen O'Connor; Jeremy Papesh; Muriel Larauche; Hannah Trost; Mayakonda N Palgunachari; G M Anantharamaiah; Harvey R Herschman; Martin G Martin; Alan M Fogelman; Srinivasa T Reddy Journal: J Clin Invest Date: 2019-06-11 Impact factor: 19.456
Authors: Abigail R Basson; Christy Chen; Filip Sagl; Ashley Trotter; Ilya Bederman; Adrian Gomez-Nguyen; Mark S Sundrud; Sanja Ilic; Fabio Cominelli; Alex Rodriguez-Palacios Journal: Front Immunol Date: 2021-02-02 Impact factor: 7.561
Authors: Jürgen Glas; Julia Seiderer; Darina Czamara; Giulia Pasciuto; Julia Diegelmann; Martin Wetzke; Torsten Olszak; Christiane Wolf; Bertram Müller-Myhsok; Tobias Balschun; Jean-Paul Achkar; M Ilyas Kamboh; Andre Franke; Richard H Duerr; Stephan Brand Journal: PLoS One Date: 2012-12-27 Impact factor: 3.240